GlassScriptPhysician profile
Danielle M Tilton
NPI 1275068652
$1,745.22
in general payments reported to CMS, 2019-2025
24 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $708 · 2022: $364 · 2023: $246 · 2024: $303 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.12 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $240.72 | 2021-2022 | |
| Esperion Therapeutics, INC. | $145.18 | 2021-2023 | Nexletol |
| Impulse Dynamics (USA) INC. | $142.68 | 2023-2025 | Optimizer, Optimizer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $139.27 | 2023-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $124.21 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.99 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $88.56 | 2021-2023 | Farxiga |
| Amgen INC. | $83.64 | 2021-2024 | Repatha |
| Amarin Pharma, INC. | $67.59 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $65.47 | 2021-2024 | Eliquis |
| Pfizer INC. | $64.99 | 2021-2025 | |
| Heartflow, INC. | $64.74 | 2023-2024 | Ffrct |
| Medtronic, INC. | $63.49 | 2022-2024 | Linq II |
| Abbott Laboratories | $60.97 | 2021-2024 | Cardiomems, Jot Dx |
| Novartis Pharmaceuticals Corporation | $60.82 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $45.16 | 2022-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $40.50 | 2021 | |
| Merck Sharp & Dohme LLC | $36.42 | 2024-2025 | Verquvo |
| Itamar Medical INC | $27.08 | 2022-2024 | Watchpatone |
| Novo Nordisk INC | $23.71 | 2025 | Ozempic |
| Astellas Pharma US INC | $21.12 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.55 | 2022 | |
| G Medical Diagnostic Services, INC. | $15.70 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Tilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.